0.552
0.15 (36.49%)
| Previous Close | 0.404 |
| Open | 0.621 |
| Volume | 285,523,574 |
| Avg. Volume (3M) | 15,565,979 |
| Market Cap | 54,764,240 |
| Price / Book | 20.19 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Operating Margin (TTM) | -333.90% |
| Diluted EPS (TTM) | -2.78 |
| Quarterly Revenue Growth (YOY) | -36.90% |
| Current Ratio (MRQ) | 1.03 |
| Operating Cash Flow (TTM) | -12.21 M |
| Levered Free Cash Flow (TTM) | -7.34 M |
| Return on Assets (TTM) | -105.59% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | PLUS THERAPEUTICS, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.38 |
|
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.02% |
| % Held by Institutions | 2.50% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Tradewinds Capital Management, Llc | 30 Jun 2025 | 200 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 5.00 (D. Boral Capital, 806.29%) | Buy |
| Median | 4.00 (625.03%) | |
| Low | 3.00 (Maxim Group, 443.77%) | Buy |
| Average | 4.00 (625.03%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 0.550 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 25 Sep 2025 | 5.00 (806.29%) | Buy | 0.560 |
| 22 Sep 2025 | 5.00 (806.29%) | Buy | 0.420 | |
| Maxim Group | 18 Aug 2025 | 3.00 (443.77%) | Buy | 0.540 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |